Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

hereditary pulmonary alveolar proteinosis News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

Exploratory data from the IMPALA-2 trial shows that molgramostim significantly improves exercise distance and duration in patients with autoimmune pulmonary alveolar proteinosis. These findings suggest potential benefits for patient mobility and quality of life.

A new study explores the use of inhaled granulocyte-macrophage colony-stimulating factor for treating autoimmune pulmonary alveolar proteinosis. This research highlights potential therapeutic pathways from understanding the disease's pathogenesis to clinical application.

A recent study highlights the comorbidity of autoimmune diseases in patients with autoimmune pulmonary alveolar proteinosis. This research may inform future clinical approaches and management strategies for affected individuals.

A case report highlights autoimmune pulmonary alveolar proteinosis induced by brigatinib, contributing to the understanding of drug-related adverse effects. This literature review may inform clinicians about potential risks associated with brigatinib treatment.

A systematic review and meta-analysis evaluates the efficacy and safety of inhaled GM-CSF in treating autoimmune pulmonary alveolar proteinosis. The findings contribute to understanding potential therapeutic options for this rare lung disease.

Savara launches an Early Access Program for molgramostim inhalation solution, aimed at patients with Autoimmune Pulmonary Alveolar Proteinosis. This initiative provides critical access to treatment for a rare disease affecting lung function.

Not rare diseases news,news about your rare disease.